Desvenlafaxine: another 'me too' drug?

Autor: Sopko MA Jr., Ehret MJ, Grgas M

Publikováno v: Annals of Pharmacotherapy; Oct2008, Vol. 42 Issue 10, p1439-1446, 8p

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Autor: Chavez B; Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, State University of New Jersey, Piscataway, NJ 07740, USA. bchavez@rci.rutgers.edu, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT

Publikováno v: The Annals of pharmacotherapy [Ann Pharmacother] 2009 Jun; Vol. 43 (6), pp. 1084-95. Date of Electronic Publication: 2009 May 26.

Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper.

Autor: Sampogna, Gaia, Caraci, Filippo, Carmassi, Claudia, Dell'Osso, Bernardo, Ferrari, Silvia, Martinotti, Giovanni, Sani, Gabriele, Serafini, Gianluca, Signorelli, Maria Salvina, Fiorillo, Andrea

Publikováno v: Expert Opinion on Pharmacotherapy; 2023, Vol. 24 Issue 14, p1511-1525, 15p

Impact on In‐ and Out‐of‐Hospital Drug Prescriptions of Including a More Expensive Me‐Too Antidepressant in a Hospital Drug Formulary: a Controlled Longitudinal Study.

Autor: Carracedo‐Martínez, Eduardo, Vázquez‐Mourelle, Raquel, Figueiras, Adolfo, Piñeiro‐Lamas, María

Publikováno v: Pharmacoepidemiology & Drug Safety; May2022, Vol. 31 Issue 5, p556-565, 10p

Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial.

Autor: Mohammadi, Mohammad Reza¹, Mohammadzadeh, Soleiman² mohammadzadeh86@gmail.com, Akhondzadeh, Shahin¹

Publikováno v: Iranian Journal of Psychiatry. Apr2015, Vol. 10 Issue 2, p106-114. 9p.